Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
DiaVacs
AddedFeb 18, 2024
UpdatedJun 18, 2026
DiaVacs

DiaVacs

Biotech firm innovating localized immunosuppression and regenerative solutions to combat autoimmune diseases.

HQ
Los Angeles, CA, US
Founded
2013
Overview
Compare
Fundraising
Employees
Website

Founded with a mission to revolutionize the treatment of autoimmune diseases, DiaVacs is a biotech firm specializing in localized immunosuppression and regenerative solutions. The company aims to halt the pathogenic autoimmune response without compromising the body's overall immune system. DiaVacs' innovative approach also complements emerging regenerative therapies by protecting newly created beta cells from autoimmune attacks, potentially freeing patients from lifelong insulin dependency.

DiaVacs has garnered attention for its groundbreaking work in the biotech industry, attracting notable investors and partnerships that have bolstered its research and development efforts. The company's achievements include significant advancements in antigen-specific immunosuppression techniques, which have shown promise in preclinical trials. DiaVacs' impact is evident in its potential to transform the management of autoimmune diseases, offering hope for improved patient outcomes and quality of life.

DiaVacs - Similar Companies

Diavibe logo

Diavibe

HI-Bio logo

HI-Bio

hibio.com

Tr1x logo

Tr1x

tr1x.bio

Vitro Biopharma logo

Vitro Biopharma

vitrobiopharma.com

ViaCyte logo

ViaCyte

Santa Ana Bio logo

Santa Ana Bio

santaanabio.com

SymbioCellTech logo

SymbioCellTech

symbiocelltech.com

ImmuneID logo

ImmuneID

Equillium logo

Equillium

equilliumbio.com

Inimmune logo

Inimmune

inimmune.com

DecImmune Therapeutics logo

DecImmune Therapeutics

decimmune.com

Immusoft logo

Immusoft

immusoft.com

Immunis logo

Immunis

Forkhead BioTherapeutics logo

Forkhead BioTherapeutics

forkheadbio.com

IM Therapeutics logo

IM Therapeutics

imtherapeutics.com

DiaVacs - Quick Facts

Who are DiaVacs' competitors?

Companies similar to DiaVacs include Diavibe, HI-Bio, Tr1x and Vitro Biopharma.

When was DiaVacs founded?

DiaVacs was founded in 2013.

Where is DiaVacs' headquarters located?

DiaVacs' headquarters is located in Los Angeles, CA, US.

When was DiaVacs' last funding round?

DiaVacs' most recent funding round was for $850k (USD) in March 2015.

How much has DiaVacs raised to-date?

As of Mar 11, 2015, DiaVacs has raised a total of $850k (USD).

How many employees does DiaVacs have?

DiaVacs has 75 employees as of Feb 5, 2024.

DiaVacs - Classification

Ownership
  • Private
Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
Main Product
  • Biotech
  • Immunotherapy
Tags
  • SaaS
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 5 more industry codes
NAICS
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified